- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.09. | Profusa receives ISO 13485 certification for quality system | 5 | Investing.com | ||
| 24.09. | Profusa erhält ISO 13485-Zertifizierung für sein Qualitätsmanagementsystem | 6 | Investing.com Deutsch | ||
| PROFUSA Aktie jetzt für 0€ handeln | |||||
| 24.09. | Profusa, Inc.: Profusa Announces Significant Progress Towards Lumee Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October | - | GlobeNewswire (USA) | ||
| 15.09. | Profusa clears Nasdaq compliance issues | 2 | Seeking Alpha | ||
| 15.09. | Profusa regains compliance with Nasdaq listing requirements | 2 | Investing.com | ||
| 15.09. | Profusa, Inc. Receives Nasdaq Compliance Determination | 167 | GlobeNewswire (Europe) | Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the "Company") announced today that on September 9, 2026, the Company received a letter (the "Compliance Determination... ► Artikel lesen | |
| 15.09. | Profusa, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.08. | Profusa regains Nasdaq compliance; shares up | 3 | Seeking Alpha | ||
| 31.08. | Profusa erfüllt wieder die Börsenanforderungen der NASDAQ | 2 | Investing.com Deutsch | ||
| 31.08. | Profusa regains compliance with Nasdaq listing requirements | 3 | Investing.com | ||
| 31.08. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.08. | Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement | 316 | GlobeNewswire (Europe) | Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the "Company") announced that it has received a letter (the "Notice") from the Listing Qualifications Department of The... ► Artikel lesen | |
| 20.08. | Profusa, Inc. reports Q2 results | 2 | Seeking Alpha | ||
| 20.08. | Profusa converts $4.6M debt to preferred stock ahead of G3 deal | 4 | Investing.com | ||
| 20.08. | Profusa, Inc.: Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company | 399 | GlobeNewswire (Europe) | Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock Sufficient working... ► Artikel lesen | |
| 20.08. | Profusa, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 19.08. | Profusa, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Profusa to implement 1-for-4 reverse stock split | 1 | Seeking Alpha | ||
| 13.08. | Profusa, Inc.: Profusa Announces 1-for-4 Reverse Stock Split | 639 | GlobeNewswire (Europe) | BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform... ► Artikel lesen |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,176 | +0,39 % | Teladoc Health Adds Contactless Vitals and Ambient AI Scribe to Virtual Visit Platform | ||
| HIMS & HERS HEALTH | 27,920 | +1,16 % | Hims & Hers Health climbs 10% amid recent volatile trading | ||
| CERENOME | 1,504 | -3,09 % | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| HEALWELL AI | 0,453 | -3,00 % | HEALWELL AI: HEALWELL AI Provides Research Update on Peer-Reviewed MyHealthNB Study and Global Recognition of DARWEN | Peer-reviewed research published in the Journal of Medical Internet Research (JMIR) reports that VeroSource's MyHealth patient app was associated with statistically significant, self-reported improvements... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,115 | 0,00 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| ORGANON | 12,290 | -0,28 % | Biotech Stocks At 52-Week Highs - AbbVie On FDA Designations, HealthStream, Organon & Co. | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on October 6, 2026, driven by catalysts such as achieving new regulatory milestones.AbbVie Inc. (ABBV)AbbVie is a biopharmaceutical... ► Artikel lesen | |
| VERU | 2,460 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 4,250 | -0,70 % | Why Is Clover Health (CLOV) Stock Soaring Today | ||
| SENSEONICS | 7,950 | -1,24 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen | |
| ELEKTA | 4,886 | +0,25 % | Elekta AB: New phase 2 data show favorable cognitive outcomes with Leksell Gamma Knife in patients with up to 50 brain metastases | BOSTON - Elekta (EKTA-B.ST) today announced new phase 2 data, presented at ASTRO by lead investigator Dr. Chia-Lin Tseng, demonstrating favorable cognitive outcomes with Leksell Gamma Knife® radiosurgery... ► Artikel lesen | |
| IMUNON | 1,030 | +7,29 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,210 | -6,44 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors | SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering... ► Artikel lesen | |
| AXOGEN | 32,920 | +2,01 % | Axogen, Inc.: Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair | ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. ("Axogen" or the "Company") (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions... ► Artikel lesen | |
| NIAGEN BIOSCIENCE | 2,120 | -2,75 % | Canaccord reiterates Niagen stock rating on healthy aging strategy | ||
| PROCEPT BIOROBOTICS | 18,400 | 0,00 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen |
Das Unternehmen PROFUSA INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROFUSA INC finden Sie auf Wallstreet Online.